secwatch.observer — SEC 8-K summary
======================================

Issuer:     FILANA THERAPEUTICS, INC. (FLNA)
CIK:        0001069530
Form:       8-K
Filed at:   2026-07-29T12:15:16+00:00
Accession:  0001171843-26-004982
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Filana Therapeutics Q2 2026 net loss $8.6M; cash $82.7M; clinical hold on TSC trial continues
--------------------------------------------------------------------------------

- Net loss of $8.6M ($0.18 per share) vs $44.2M ($0.92) in Q2 2025; improvement due to no repeat of $31.25M litigation loss.
- Cash and equivalents $82.7M at June 30, 2026, down from $95.5M at Dec 31, 2025; no debt.
- R&D expenses $3.3M (down 35% YoY) as Alzheimer's program phased out; G&A $6.1M (down 85% YoY).
- Paid $31.25M into escrow on July 23, 2026 for securities litigation settlement; cash restricted pending court approval.
- Unrestricted cash at year-end 2026 expected $36-40M; second-half 2026 operating cash use $11-15M plus litigation funding.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1069530/000117184326004982/0001171843-26-004982-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1069530/000117184326004982/f8k_072826.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-004982

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer